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Application of Red Cell Membrane 
in Nanobiotechnology
Insu Kim, Gyudo Lee and Dae Sung Yoon
Abstract
Red cells are full of unique biological properties such as immune evasion and 
molecular-specific permeability. These properties originate from various membrane 
proteins on the surface of the cell membrane. For this reason, red cell membrane is 
coated on nanomaterials or sensors to bestow the functionalities of the membrane 
proteins. In this chapter, various types of membrane proteins of red cell and its 
functions are described. Also, the following two experimental procedures are sum-
marized: (I) the extraction of red cell membrane containing membrane proteins 
and (II) coating of the extracted cell membrane onto the nanoparticles and solid 
surface of sensors. Finally, the applications of red cell membrane in drug delivery 
system and biosensor are discussed.
Keywords: red cell membrane, membrane proteins, cell membrane coating, 
biosensors
1. Introduction
Red cells (RCs), also called as erythrocyte, are the most abundant cells in the 
body and highly specialized in gas transportation [1]. RCs deliver oxygen from 
the lungs to all body tissues and carry carbon dioxide to the lungs. For the delivery 
of the gases, RCs circulate through blood vessels to the whole body without being 
trapped inside narrow capillary vessels (5–10 μm in diameter) which are smaller 
than the size of RCs [2]. Also, RCs do not get attacked by immune system such as 
mononuclear phagocytic system (MPS) and complement system (CS) [3, 4]. The 
unique characteristics of the RCs come from specialized microstructure of RC. The 
microstructure of RC has a biconcave disc-like shape and is fully packed with 
hemoglobin instead of nucleus and intracellular organelles. Also, various membrane 
proteins and carbohydrates are embedded in the cell membrane which character-
izes intrinsic functionalities of RCs [5]. The biconcave disc-like shape maximizes 
the surface area of the cell, which increases the gas exchanges between internal 
and external gases. Hemoglobins are oxygen-transport metalloproteins that bind 
gases such as oxygen and carbon dioxide. Especially, membrane proteins of RC are 
responsible for numerous characteristics such as permeability to specific molecules 
(e.g., glucose, urea, and gases), immune evasive properties, unique biconcave 
disc-like structure, flexibility, and deformability [4, 6]. Recently, it is reported 
that membrane proteins of RC can be utilized by manipulating the cell membrane 
[7]. The RC membrane (RCM) inside the whole blood of mice or human contains 
membrane proteins, which were extracted and purified. Accordingly, intriguing 
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researches were conducted together. For example, just like RC does, RCM-coated 
nanoparticles showed long circulation in the blood by evading immune responses 
such as MPS and CS [7, 8]. Also, RCM-coated glucose sensors showed high perm-
selectivity to glucose [9]. As a result, the sensor was barely affected by interfering 
molecules such as saccharides and antioxidants. Likewise, the utilization of the 
functionalities of membrane protein of RC advances nanobiotechnology in the field 
of drug delivery system and biosensor. In this chapter, we investigate the various 
membrane proteins expressed on RC and its functionalities. The techniques for 
extraction and functionalization of cell membrane have been researched. Also, we 
discuss about the application of RCM functionalization for the last decade.
2. Membrane proteins of red cell membrane and its functionalities
Membrane proteins are essential components allowing specific functionalities 
for cells. There are three categories classified by its function. Membrane proteins 
perform as receptors, transporters, and cell adhesion molecules. Table 1 represents 
major membrane proteins on RCM classified by their function [5].
2.1 Membrane receptors
Membrane receptors are one of integral membrane proteins. They mediate cell 
signaling via binding extracellular molecules. Specifically, membrane receptors 
allow communication between the cell and external environment. Hormones, cyto-
kines, cell adhesion molecules, and immunoproteins are examples of the extracel-
lular molecules. The ligand bound of the membrane receptor may induce changes in 
the metabolism or activity of the cell. In RC, CD55 (decay-accelerating factor) and 
Protein Gene Function
Membrane receptor
CD55 (aDAF) CD55 Decay-accelerating factor that prevents the activation of 
complement system
CD59 CD59 bMAC-inhibitory protein that prevents complement membrane 
attack complex
Transporter
AE1 (band 3) SLC4A1 Anion transporter
RhAG RhAG Ammonia transporter
Nucleoside transporter SLC29A1 Nucleoside transporter
Urea transporter SLC14A1 Urea transporter
Glucose transporter SLC2A Glucose transporter
Cell adhesion molecule
CD47 CD47 “do not eat me” signal protein that interacts with cSIRPα to 
inhibit phagocytosis
Membrane receptors consist of CD55 and CD59; transporters consist of AE1, RhAG, nucleoside transporter, urea 
transporter, and glucose transporter; cell adhesion molecule consists of CD47.
aDAF, decay-accelerating factor.
bMAC, membrane attack complex.
cSIRPα, signal regulatory protein alpha.
Table 1. 
Various membrane proteins in RCs [5].
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CD59 are well-known membrane receptors which inhibit CS preventing hemolysis 
(Figure 1) [10]. In detail, CS is composed of proximal and terminal complement 
(Figure 2) [4]. The proximal CS has three pathways converged at the step of 
complement component 3 (C3) activation. The terminal complement is initiated 
with complement component 5 (C5) and ended with formation of membrane attack 
complex (MAC). In this cascade, CD55 inhibits C3 activation by deactivating C3 
convertase [11]. CD59 inhibits terminal complement activation by preventing the 
formation of MAC that starts with the activation of C5 [12]. The absence of CD55 
and CD59 may lead to hemolysis of RC via complement activation [4].
2.2 Transporters
Transporters are involved in the movement of specific molecules or ions across 
cell membrane. The proteins are involved in the movement of molecules by active 
transport or facilitated diffusion. It is revealed that anion, gas, nucleoside, urea, and 
glucose transporters are expressed on the RC. In detail, (AE1, also called band 3) is 
responsible for mediating the exchange of chloride ion with bicarbonate (HCO3ˉ) 
across RCM [13]. Rh-associated glycoprotein (RhAG) is a gas transporter which 
permeates carbon dioxide [1]. Nucleoside transporter mediates the transport of 
nucleoside substrates like adenosine [14]. Urea transporter is specialized in urea 
transportation, which is activated by antidiuretic hormone (vasopressin) [15]. 
Glucose transporter (GLUT) is a uniporter that transports glucose toward intracel-
lular orientation (Figure 3) [16]. GLUT is an essential protein for glucose uptake of 
the cell by catalyzing facilitative diffusion. Especially, RC expresses a large number 
of GLUT compared to other cells because the cell lacks mitochondria and the energy 
is produced by glycolysis of glucose [17].
Figure 1. 
Hemolysis mechanism of paroxysmal nocturnal hemoglobinuria (PNH) via the complement system [4]. (a) 
Normal RBC possesses CD55 and CD59 which are glycosylphosphatidylinositol (GPI)-anchored self-protective 
complement regulatory factors. CD55 is a widely expressed membrane protein that accelerates the decay of C3 
convertases. CD59 is the major inhibitor of terminal complement, which blocks the generation of the membrane 
attack complex (MAC). (b) Intravascular hemolysis of PNH RBC through C3 convertase and MAC.  
(c) Extravascular hemolysis of PNH RBC via macrophage. Eculizumab inhibits the complement activation 
by compensating CD59. *PNH, a life-threatening disease characterized by destruction of RBC by complement 
system; eculizumab, a monoclonal antibody complement inhibitor which is highly effective for PNH; C3 con, 
C3 convertase; C5b-8, complex of C5b, C6, C7, and C8 proteins; C3dg, a fragment of C3 protein, which is 
ligand of integrin (CR3) on macrophage; iC3b, inactivated C3b; Hb, hemoglobin; CR3, complementary 3.
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Figure 2. 
Complement system signal cascade [4]. Proximal complement consists of three pathways. The lectin, classical, 
and alternative pathways initiate and converge at the step of complement component 3 (C3) activation. 
Terminal complement is initiated by C5 convertases, leading to cleavage of C5 to C5a and C5b. C5b oligomerizes 
with C6, C7, C8, and multiple C9 molecules to form the membrane attack complex (MAC). The CD55 inhibits 
proximal complement activation by accelerating the decay of C3 convertases preventing the incorporation of C9 
into the MAC.
Figure 3. 
(a) Overall structure of human glucose transporter-1 (GLUT1) and (b) working model for GLUT1 [16]. The 
working model is predicted to have four conformations (outward open, ligand-bound and occluded, inward-
open, and ligand-free and occluded) required for a complete glucose transport cycle. Intracellular helix (ICH) 
domain of GLUT1 has two critical roles. First, the ICH domain appears to maintain a defined conformation 
with respect to the N domain. Second, the ICH domain is pulled toward the C domain during the inter-domain 
rotation from occluded to inward-open conformation.
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2.3 Cell adhesion molecules
Cell adhesion molecules interact with membrane receptors of various cells. RC 
has CD47 as a cell adhesion molecule [18]. CD47 belongs to the immunoglobulin 
superfamily and sends a “don’t eat me” signal to MPS such as monocyte and macro-
phage (Figure 4) [6]. This intriguing signal is derived from the interaction between 
CD47 and signal regulatory protein alpha (SIRPα) which is expressed on monocytes 
and most of subpopulations such as macrophages. Indeed, CD47-eliminated RCs 
were easily phagocytosed by macrophages unlike RC with CD47 [3, 19].
3. Red cell membrane extraction and functionalization techniques
3.1 Red cell membrane extraction procedure
RC can easily be extracted from whole blood of mice or human. Normally, the 
whole blood is extracted at vacutainer tube (evacuated tube) containing anti-
coagulant such as heparin, citrate, or ethylenediaminetetraacetic acid (EDTA) 
according to the purpose (Table 2). Heparin collection tubes are preferred for 
peripheral blood in cytogenic studies. Heparin activates antithrombin III which 
deactivates thrombin and serine endopeptidase, which are essential enzymes for 
coagulation [20]. Citrate collection tubes are employed for blood transfusion and 
coagulation assays because citrate reversibly binds to calcium which is an essen-
tial molecule in many steps of coagulation cascade [21]. EDTA collection tubes 
are usually used for complete blood count (CBC) test because EDTA is a strong 
anticoagulant that irreversibly binds to calcium [22]. Since coagulation requires 
RC to form blood clot, EDTA collection tubes are mostly used for RC extraction 
[7, 8, 23].
The procedure for extracting RC from whole blood is as follows [23]. Whole 
blood withdrawn from mice or human is centrifuged at 800–1000 g for 5 min at 4°C 
in order to remove the plasma and the buffy coat. The resulting sediment is washed 
three times with ice-cold 1× PBS to remove blood proteins adsorbed on RCs. To 
extract cell membrane from RCs, hypotonic treatment, homogenize, or sonication 
is conducted for hemolysis. Hypotonic treatment is the most convenient hemolysis 
procedure without disruption of membrane and membrane proteins. Washed RCs 
are suspended in 0.25× PBS for 20 min at 4°C. As hemolysis progresses, hemoglobin 
is released from RCs, and RC ghosts (empty cell membrane without cytoplasmic 
contents) are formed [24]. As a result, RC ghost can be verified with phase contrast 
Figure 4. 
The cocrystal structure shows human CD47 (hCD47) with human signal regulatory protein α (hSIRPα). The 
left panel depicts that the occurrence of phagocytosis depends on the reaction between hCD47 and hSIRPα [6].
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microscope. To remove the hemoglobin, hemolyzed solution is centrifuged and 
washed. Then the RCM is collected with light pink pellet. The resulting RCM 
concentrate is stored in −70°C before use.
3.2 Red cell membrane coating techniques on nanoparticle and solid surface
Cell membrane coating technology comes from phospholipid manipulation 
technique which forms liposome and solid-supported lipid bilayer because the 
phospholipids are the main component of cell membrane. Although the phos-
pholipid manipulation technique was developed quite a while ago, cell membrane 
coating techniques on nanoparticles were first reported in 2011 (Figure 5) [7]. 
Researchers prepared RCM-coated nanoparticles by RCM vesicle-nanoparticle 
fusion [25, 26]. Specifically, the extracted cell membrane was adequately diluted 
(membrane extraction was described in Section 3.1.). For the membrane vesicle 
derivation, outer forces are applied to the diluted membrane. Sonicating the 
membrane is the easiest way to make membrane vesicle, but it is hard to regulate 
the size of the vesicle. Alternatively, extrusion methods can control the size of the 
membrane vesicle by porous polymer membrane with various pore sizes. Next, 
membrane coating onto nanoparticles is conducted with the same procedure to 
Anticoagulant Usage Mechanism
Heparin Cytogenetic studies Activate antithrombin III which 
deactivates serum clotting factors 
(factors aIIa and bXa)
Citrate Coagulation assays, blood 
transfusion
Bind to calcium reversibly (not as 
strong as EDTA)
Ethylenediaminetetraacetic acid 
(EDTA)
molecular genetic studies, 
complete blood counts
Strongly bind to calcium irreversibly. 
The absence of calcium
aFactor IIa, thrombin.
bfactor Xa, serine endopeptidase.
Table 2. 
Vacutainers with various anticoagulants.
Figure 5. 
The schematic illustration of the preparation of RBC membrane-coated polymeric nanoparticles [7]. RBCs, red 
blood cell; polymeric NP, polymeric nanoparticle such as poly(lactic-co-glycolic acid) (PLGA) nanoparticle.
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vesicle formation (i.e., sonication or extrusion). In detail, the prepared membrane 
vesicles are mixed with nanoparticles. Then the sonication or extrusion of the mix-
ture can lead to the coating of membrane onto the nanoparticles by the principle of 
vesicle fusion.
The cell membrane coating on solid surface is similar to that on nanopar-
ticles described above. The coating procedure is based on vesicle fusion method 
(Figure 6) [27]. The only different procedure for solid surface coating is that 
thermal energy is employed instead of mechanical energy (i.e., sonication or 
extrusion) [9, 28]. Specifically, the cell membrane vesicles with adequate con-
centration were placed on solid surface and incubated for 45 min at 50°C. The 
thermal energy induces the membrane vesicle to collide and fuse onto the solid 
surface. It is noted that the temperature for vesicle fusion should be lower than 
the denaturation temperature of proteins to avoid the deactivation or misfolding 
by high thermal energy [29].
4.  The applications of red cell membrane in drug delivery systems and 
biosensors
RCM-coated nanoparticles, also called RC-camouflaged nanoparticles, have been 
developed for drug delivery system since they were devised by Zhang and his group 
in 2011. It was found that immune evasive properties of RCM-coated nanopar-
ticles are superior to conventional nanoparticles. The membrane proteins confer 
the advantages of the immune avoidance properties described in Section 2. RCM 
coating has been applied to various core nanoparticles such as gold, poly(lactic-co-
glycolic acid) (PLGA), silica, and iron oxide nanoparticles [30]. Also, RCM can be 
utilized as permselective filter for glucose biosensor taking advantage of GLUT on 
RCM [9].
4.1 Drug delivery with red cell membrane-coated nanoparticles
In drug delivery system related with nanomaterial, long-term circulation of 
nanoparticles in vivo is one of the most important characteristics because vari-
ous immune responses clear the foreign molecules in the body and blood [31]. 
Especially, MPS and CS are major immune systems eliminating drug delivery carri-
ers. Conventionally, to evade the immune systems, the drug carriers are functional-
ized with polyethylene glycol (PEG) which slows clearance in blood and avoids 
non-specific binding of blood proteins [32, 33]. In our body, however, there is an 
anti-PEG immunological response which removes PEGylated nanoparticles [34]. 
By contrast, the RCM-coated nanoparticles showed prolonged circulation in blood. 
The result is exactly attributed to membrane receptors and cell adhesion molecules, 
Figure 6. 
Fusion of a lipid vesicle on solid surface [27].
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which were abundant and diverse on RCM. In this regard, the immune evasive 
properties of RCM-functionalized nanomaterials have great potential as clinical 
drug delivery carriers. In particular, it is researched that the RCM-functionalized 
nanoparticles showed good dispersion stability in serum and great biodistribution 
in mice model up to 72 h (Figure 7) [7]. Indeed, it is demonstrated that the RCM 
inhibits macrophage uptake. RCM-coated gold nanoparticles showed ~4 times 
higher immune evasive properties than bare gold nanoparticles [8].
4.2 Permselective glucose sensing with red cell membrane-coated biosensors
In biosensors, not only sensitivity but also specificity (selectivity) is impor-
tant because numerous molecules coexist in the biological samples that may 
interfere the detection [35]. For example, blood contains ions, saccharides, pro-
teins, and blood cells which hinder accurate glucose detection. Enzymatic glucose 
biosensors, most widely used, employ glucose oxidase or glucose dehydrogenase 
Figure 7. 
Biodistribution of RCM-coated gold nanoparticles in mice [7]. The fluorescently labeled nanoparticles were 
injected intravenously into the mice. The fluorescent intensity at the liver, kidney, spleen, brain, lung, heart, 
and blood was measured at 24, 48, and 72 h. (A) fluorescent intensity per gram of tissue (n = 6). (B) Relative 
signal per organ.
Figure 8. 
Schematic illustration of RCM-coated glucose sensor [9]. The RCM-coated enzymatic glucose sensor specifically 
reacts with glucose via taking advantage of glucose transporter-1 (GLUT1).
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for selective detection of glucose. However, the enzymes react with glucose and 
other similar structured molecules (mono- and disaccharides) such as fructose, 
galactose, and maltose in blood. For this reason, glucose sensors are interfered 
by the molecules. It is reported that RCM which has glucose transporter was 
employed as glucose-selective permeable membrane by taking advantage of 
GLUT (Figure 8) [9]. The RCM-coated sensor showed high selectivity to glucose 
compared to uncoated sensor. In detail, the uncoated sensors are highly affected 
by the increment of interfering molecules (e.g., ascorbic acid, uric acid, and 
galactose), whereas the RCM-coated sensors exhibit consistency in glucose 
detection. In particular, RCM-coated sensor showed that the signals of glucose 
with interfering molecules barely change from that of glucose without interfering 
molecules (Figure 9) [9].
5. Conclusions
The RCM has various types of membrane proteins such as membrane receptor, 
transporter, and cell adhesion molecules. Each type of membrane proteins is full in 
potentials to be applied in various fields such as drug delivery system and biosen-
sor. The well-evolved functionality of membrane proteins can be easily utilized 
by coating the RCM on nanomaterial and solid surface of sensors. Currently, drug 
delivery system is the major field of RCM application because the membrane can 
confer the immune evasive properties of RCM to the nanomaterials. In the future, 
it is expected that the RCM will be increasingly applied in development of highly 
selective biosensors utilizing various transporters on RCM.
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